Ranbaxy Board Approves Spin-off Of Drug Discovery Company
This article was originally published in The Pink Sheet Daily
Indian firm reports $1.2 billion in sales for the first nine months of 2007.
You may also be interested in...
Ranbaxy is looking for more strategic product acquisitions to build its branded division, firm tells “The Pink Sheet” DAILY.
Ranbaxy will develop a respiratory disease candidate through proof of concept under an expanded discovery agreement inked with GSK in February.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.